Full Program Just Released!
Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Alice Yam

Alice Yam

Vice President, Early Development & Strategic Program Management Sutro Biopharma

Seminars

Tuesday 13th October 2026

Driving Clinical Success With STRO-006: Breaking Down Insights From PDX Response & Translational Biomarkers

12:00 pm

Outlining design and development of STRO-006, an integrin beta-6 targeted DAR8 Topo1 ADC
Evaluating STRO-006 in a PDX clinical trial to identify biomarkers correlating with response
Undergoing translational workstreams to enable successful clinical development

Alice Yam

View all Speakers

View Event Brochure